LTPA2021511I1 - - Google Patents

Info

Publication number
LTPA2021511I1
LTPA2021511I1 LTPA2021511C LTPA2021511C LTPA2021511I1 LT PA2021511 I1 LTPA2021511 I1 LT PA2021511I1 LT PA2021511 C LTPA2021511 C LT PA2021511C LT PA2021511 C LTPA2021511 C LT PA2021511C LT PA2021511 I1 LTPA2021511 I1 LT PA2021511I1
Authority
LT
Lithuania
Application number
LTPA2021511C
Other languages
Lithuanian (lt)
Original Assignee
Pearl Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2021511(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pearl Therapeutics, Inc. filed Critical Pearl Therapeutics, Inc.
Publication of LTPA2021511I1 publication Critical patent/LTPA2021511I1/lt
Publication of LTC2435024I2 publication Critical patent/LTC2435024I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1025—Respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
LTPA2021511C 2009-05-29 2021-06-04 LTC2435024I2 (enExample)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18256509P 2009-05-29 2009-05-29
US25817209P 2009-11-04 2009-11-04
US30936510P 2010-03-01 2010-03-01
US34553610P 2010-05-17 2010-05-17
PCT/US2010/036650 WO2010138862A2 (en) 2009-05-29 2010-05-28 Compositions for respiratory delivery of active agents and associated methods and systems

Publications (2)

Publication Number Publication Date
LTPA2021511I1 true LTPA2021511I1 (enExample) 2021-06-25
LTC2435024I2 LTC2435024I2 (enExample) 2022-06-27

Family

ID=42269864

Family Applications (8)

Application Number Title Priority Date Filing Date
LTEP10727553.9T LT2435025T (lt) 2009-05-29 2010-05-28 Veikliosios medžiagos tiekimas per kvėpavimo takus
LTEP10721258.1T LT2435023T (lt) 2009-05-29 2010-05-28 Kompozicijos, skirtos ilgai veikiančių muskarininių antagonistų ir ilgai veikiančių beta-2-adrenerginio receptoriaus agonistų pristatymui į plaučius, ir susiję būdai bei sistemos
LTEP16164849.8T LT3111927T (lt) 2009-05-29 2010-05-28 Kompozicijos veikliųjų agentų respiraciniam peteikimui ir susiję būdai ir sistemos
LTEP10727551.3T LT2435024T (lt) 2009-05-29 2010-05-28 Kompozicijos aktyvių agentų pristatymui į kvėpavimo takus ir susiję būdai bei sistemos
LTEP16164844.9T LT3111926T (lt) 2009-05-29 2010-05-28 Kompozicijos, būdai ir sistemos dviejų arba kelių veikliųjų agentų respiraciniam pateikimui
LTEP16164845.6T LT3106149T (lt) 2009-05-29 2010-05-28 Kompozicijos, skirtos ilgo poveikio muskarino antagonistų ir ilgo poveikio beta 2 adrenerginio receptorius agonistų pateikimui į plaučius, ir susiję būdai ir sistemos
LTPA2019014C LTC2435025I2 (lt) 2009-05-29 2019-06-17 Veikliosios medžiagos tiekimas per kvėpavimo takus
LTPA2021511C LTC2435024I2 (enExample) 2009-05-29 2021-06-04

Family Applications Before (7)

Application Number Title Priority Date Filing Date
LTEP10727553.9T LT2435025T (lt) 2009-05-29 2010-05-28 Veikliosios medžiagos tiekimas per kvėpavimo takus
LTEP10721258.1T LT2435023T (lt) 2009-05-29 2010-05-28 Kompozicijos, skirtos ilgai veikiančių muskarininių antagonistų ir ilgai veikiančių beta-2-adrenerginio receptoriaus agonistų pristatymui į plaučius, ir susiję būdai bei sistemos
LTEP16164849.8T LT3111927T (lt) 2009-05-29 2010-05-28 Kompozicijos veikliųjų agentų respiraciniam peteikimui ir susiję būdai ir sistemos
LTEP10727551.3T LT2435024T (lt) 2009-05-29 2010-05-28 Kompozicijos aktyvių agentų pristatymui į kvėpavimo takus ir susiję būdai bei sistemos
LTEP16164844.9T LT3111926T (lt) 2009-05-29 2010-05-28 Kompozicijos, būdai ir sistemos dviejų arba kelių veikliųjų agentų respiraciniam pateikimui
LTEP16164845.6T LT3106149T (lt) 2009-05-29 2010-05-28 Kompozicijos, skirtos ilgo poveikio muskarino antagonistų ir ilgo poveikio beta 2 adrenerginio receptorius agonistų pateikimui į plaučius, ir susiję būdai ir sistemos
LTPA2019014C LTC2435025I2 (lt) 2009-05-29 2019-06-17 Veikliosios medžiagos tiekimas per kvėpavimo takus

Country Status (31)

Country Link
US (12) US20110132357A1 (enExample)
EP (6) EP2435025B1 (enExample)
JP (10) JP5873013B2 (enExample)
KR (7) KR101748892B1 (enExample)
CN (6) CN107669664B (enExample)
AR (3) AR076621A1 (enExample)
AU (3) AU2010253776B2 (enExample)
BR (3) BRPI1011508A2 (enExample)
CA (3) CA2763941A1 (enExample)
CY (8) CY1118034T1 (enExample)
DK (6) DK3106149T3 (enExample)
ES (6) ES2772253T3 (enExample)
FR (1) FR19C1040I2 (enExample)
HR (6) HRP20161101T1 (enExample)
HU (8) HUE031283T2 (enExample)
IL (3) IL216468B (enExample)
LT (8) LT2435025T (enExample)
LU (2) LUC00124I2 (enExample)
ME (1) ME03631B (enExample)
MX (5) MX377778B (enExample)
NL (1) NL300995I2 (enExample)
NO (2) NO2019026I1 (enExample)
PH (1) PH12017500778A1 (enExample)
PL (6) PL3111927T3 (enExample)
PT (6) PT3106149T (enExample)
RU (5) RU2713404C2 (enExample)
SI (6) SI3111927T1 (enExample)
SM (6) SMT202000077T1 (enExample)
TW (9) TWI633898B (enExample)
WO (3) WO2010138862A2 (enExample)
ZA (4) ZA201108275B (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
US10002325B2 (en) 2005-03-30 2018-06-19 Primal Fusion Inc. Knowledge representation systems and methods incorporating inference rules
WO2007033372A2 (en) 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
CA3153292A1 (en) 2008-06-13 2009-12-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN102065942B (zh) 2008-06-20 2013-12-11 曼金德公司 用于对吸入工作进行实时描绘的交互式设备和方法
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP2435025B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Respiratory delivery of active agents
RU2571331C1 (ru) * 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
US10474647B2 (en) 2010-06-22 2019-11-12 Primal Fusion Inc. Methods and devices for customizing knowledge representation systems
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
PH12013502270A1 (en) * 2011-05-17 2014-01-27 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of two or more active agents
CN105106200A (zh) * 2011-05-17 2015-12-02 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
CA2869849A1 (en) * 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
CN102872027B (zh) * 2012-09-18 2014-03-12 刘晓忠 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备
JP6426624B2 (ja) * 2013-01-28 2018-11-21 インコゼン・セラピューティクス・プライベート・リミテッド ロフルミラストｎ−酸化物の吸入によって自己免疫、呼吸器性および炎症性の障害を処置する方法
US9682038B2 (en) * 2013-01-31 2017-06-20 Prosonix Limited Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
GB201301721D0 (en) * 2013-01-31 2013-03-20 Prosonix Ltd Pharmaceutical Preparations
PT2964199T (pt) * 2013-03-04 2020-05-12 Besins Healthcare Lu Sarl Composições farmacêuticas secas compreendendo nanoparticulas do agentes ativos, limitadas a partículas transportadoras
MX2015012529A (es) * 2013-03-14 2016-07-05 Novartis Ag Deamorfizacion de formulaciones secadas por pulverizacion a traves de pulverizacion de la mezcla.
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
JP2016519160A (ja) * 2013-05-22 2016-06-30 パール セラピューティクス，インコーポレイテッド ３つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム
CA2918369C (en) 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US20160243320A1 (en) * 2013-10-07 2016-08-25 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhaler
EA201691068A1 (ru) * 2013-11-22 2016-09-30 Тева Брэндид Фармасьютикал Продактс Ар Энд Ди, Инк. Ингалируемое лекарственное средство
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
CN104188941B (zh) * 2014-09-02 2016-11-16 重庆和平制药有限公司 一种制备盐酸克仑特罗吸入粉雾剂的方法
CA2961660A1 (en) * 2014-10-01 2016-04-07 Als Mountain Llc Pharmaceutical composition comprising aspirin, metformin, and serotonin with non-ionic surfactant
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
TW201735914A (zh) 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
CN108883079A (zh) * 2016-03-15 2018-11-23 广东东阳光药业有限公司 喷雾剂、喷雾装置以及喷雾组件
US20190269703A1 (en) * 2016-05-17 2019-09-05 Mayo Foundation For Medical Education And Research Materials and methods for treating chronic cough
WO2018002779A1 (en) 2016-06-30 2018-01-04 Philip Morris Products S.A. Nicotine particles
EP3607936B1 (en) 2016-09-19 2023-11-08 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising glycopyrrolate
JP6906947B2 (ja) * 2016-12-22 2021-07-21 キヤノン株式会社 画像処理装置、撮像装置、画像処理方法およびコンピュータのプログラム
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
CN107243080B (zh) * 2017-06-21 2021-11-12 上海上药信谊药厂有限公司 一种吸入式气雾剂、其原料组合物及制备方法
EP4091652B1 (en) * 2017-10-09 2023-11-29 Pearl Therapeutics, Inc. Aerosol delivery unit
JP7372727B2 (ja) 2017-11-20 2023-11-01 三菱重工業株式会社 系統運用者側コンピュータ、発電事業者側コンピュータ、電力システム、制御方法及びプログラム
WO2020070620A2 (en) * 2018-10-01 2020-04-09 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
JP7090941B2 (ja) * 2018-10-02 2022-06-27 学校法人 名城大学 吸入粉末剤、その評価方法及びその用途
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法
WO2020229966A1 (en) * 2019-05-10 2020-11-19 Glenmark Pharmaceutical Limited Stable aerosol composition for inhalation comprising glycopyrronium
CN112137957B (zh) 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2020263994A1 (en) * 2019-06-27 2020-12-30 Cai Gu Huang Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromide
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
JP2023513969A (ja) * 2020-02-20 2023-04-04 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 緩衝化医薬製剤を含む加圧定量吸入器
JP2023526098A (ja) 2020-05-18 2023-06-20 オレクソ・アクチエボラゲット 薬物送達のための新しい医薬組成物
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
WO2022016068A1 (en) * 2020-07-16 2022-01-20 Tbd Pharma Llc Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections
CN116963715A (zh) 2020-09-29 2023-10-27 艾罗克斯医疗有限责任公司 茚达特罗的液体配制品
TW202241410A (zh) * 2021-01-08 2022-11-01 大陸商江蘇恒瑞醫藥股份有限公司 可經由定量吸入器遞送的藥物組合物
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
MA60224B1 (fr) 2021-07-09 2024-06-28 Astrazeneca Pharmaceuticals Lp Compositions, méthodes et systèmes pour l'administration d'un médicament en aérosol
CA3238850A1 (en) 2021-11-25 2023-06-01 Jonas Savmarker Pharmaceutical composition comprising adrenaline
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
CN118414148A (zh) 2021-12-20 2024-07-30 阿斯利康(瑞典)有限公司 用于气溶胶药物递送的组合物、方法和系统
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
JP2025518628A (ja) 2022-04-28 2025-06-18 アストラゼネカ・アクチエボラーグ 喘息の治療のための医薬組成物及び方法
WO2024206662A1 (en) * 2023-03-30 2024-10-03 Aerorx Therapeutics Llc Liquid formulations of indacaterol and glycopyrronium
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用
US20250268914A1 (en) * 2024-02-26 2025-08-28 Honeywell International Inc. Fluticasone delivery compositions, devices and methods
CN118787617A (zh) * 2024-09-14 2024-10-18 苏州易合医药有限公司 一种吸入粉剂及其制备方法

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (enExample) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
CY1359A (en) * 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
EP0416950B1 (en) 1989-09-08 1993-08-11 Glaxo Group Limited Medicaments
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
IL99437A (en) 1990-09-10 1995-05-29 Schering Corp Mometasone furoate monohydrate process for making same and pharmaceutical compositions
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
US5635563A (en) 1991-04-01 1997-06-03 Tomoegawa Paper Co., Ltd. Polyaniline derivatives and their production process
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
JP3342484B2 (ja) 1991-12-18 2002-11-11 アストラ・アクチエボラーグ 新規な配合
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5849263A (en) 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
PT731688E (pt) 1993-12-02 2003-07-31 Abbott Lab Formulacoes de farmacos em aerossol para utilizacao com propulsores sem cfc
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
NZ279549A (en) 1994-02-09 1996-11-26 Kinerton Ltd Obtaining solid material by drying a solution thereof, supercooled spray of solution expanded into vacuum and frozen droplets collected
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
EE9700138A (et) * 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
ES2237767T3 (es) * 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
DE19614421C2 (de) 1996-04-12 1999-12-16 Biovision Gmbh Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff
GB9610821D0 (en) 1996-05-23 1996-07-31 Glaxo Wellcome Inc Metering apparatus
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
ATE238280T1 (de) * 1996-11-11 2003-05-15 Christian R Noe Verwendung eines pharmazeutisch geeigneten salzes von (3r,2'r)-3-((cyclopentyl- hydroxyphenylacetyl)oxy)-1,1-dimethyl- pyrrolidinium zur herstellung eines arzneimittels
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
PL192441B1 (pl) 1997-03-20 2006-10-31 Schering Corp Sposób wytwarzania aglomeratów i postać dawkowania środka farmakologicznie aktywnego
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
AU750567B2 (en) 1997-09-29 2002-07-25 Novartis Ag Stabilized preparations for use in nebulizers
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
KR20010041605A (ko) 1998-03-05 2001-05-25 요시다 쇼지 안저 조직 세포병리와 관련된 질환의 예방 및 치료용 제약조성물
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6260549B1 (en) * 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6585958B1 (en) 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
WO2000007567A1 (de) * 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
DK1131059T3 (da) * 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
GB9912639D0 (en) * 1999-05-28 1999-07-28 Britannia Pharmaceuticals Ltd Improvements in and relating to treatment of respiratory conditions
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
KR20010099865A (ko) 1998-12-22 2001-11-09 프란시스 제이 메이어 기도 질병 치료용 화합물과 그의 치료 방법 및 기도약물의 전달 방법
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
AU3409399A (en) 1999-03-05 2000-09-28 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
PT1169019E (pt) 1999-04-14 2003-07-31 Glaxo Group Ltd Formulacao farmaceutica em aerossol
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
ATE371490T1 (de) 1999-06-30 2007-09-15 Nektar Therapeutics Verfahren und system zur herstellung von trockenem pulver mittels sprühtrocknung
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
PT102343B (pt) 1999-08-02 2003-11-28 Hovione Farmaciencia Sa Processo para a preparacao de furoato mometasona
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
IL149085A0 (en) 1999-10-29 2002-11-10 Inhale Therapeutic Syst A dry powder composition containing a di or tripeptide
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
AU2001252350A1 (en) 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
WO2002014293A1 (en) 2000-08-15 2002-02-21 Carsten Berg Quaternary ammonium salts of 1,2-benzisothiazolin-3-one. preparation and use as biocides
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
EP1337240B2 (en) * 2000-11-30 2014-09-24 Vectura Limited Method of making particles for use in a pharmaceutical composition
EP2298285A3 (en) 2000-11-30 2011-07-27 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
AU2002230993B2 (en) 2000-12-29 2006-02-02 Alkermes, Inc. Particles for inhalation having sustained release properties
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
IL157580A0 (en) * 2001-03-20 2004-03-28 Glaxo Group Ltd Inhalation drug combination
WO2002078761A1 (fr) * 2001-03-30 2002-10-10 Laboratoires Genevrier Neo-tissu cartilagineux greffable
RO121172B1 (ro) * 2001-03-30 2007-01-30 Jago Research Ag Compoziţie farmaceutică de aerosol şi utilizarea acesteia
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
DE10202940A1 (de) * 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
DE10214264A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
CN101700247A (zh) * 2002-06-12 2010-05-05 埃匹吉尼斯医药有限公司 利用脱氢表雄酮甾体及抗毒蕈碱药物治疗呼吸道疾病及肺病的组合物、制剂和试剂盒
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
DE10237739A1 (de) 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
EP1542753B1 (en) 2002-08-23 2007-02-07 Schering Corporation Pharmaceutical compositions
CA2500065A1 (en) 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
JP4074622B2 (ja) * 2002-10-15 2008-04-09 クライオバック・インコーポレイテツド 脱酸素剤を賦活化し、保存し、かつ配送するための方法、および保存された脱酸素剤
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
DE10323966A1 (de) 2003-05-27 2004-12-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
KR20120080243A (ko) 2003-05-28 2012-07-16 노바르티스 아게 아미노산 및/또는 인지질로 부분 또는 완전 코팅된 수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의 분무 건조법
ES2383206T3 (es) 2003-06-16 2012-06-19 Nycomed Gmbh Composición que comprende un tensioactivo pulmonar y sildenafilo para el tratamiento de neumopatías
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
ATE420641T1 (de) 2003-07-28 2009-01-15 Boehringer Ingelheim Int Medikamente zur inhalation mit betamimetika und einem anticholinergikum
BRPI0413129A (pt) 2003-07-29 2006-10-03 Boehringer Ingelheim Int medicamentos para inalação compreendendo betamiméticos e anticolinérgico
KR20060052912A (ko) 2003-07-29 2006-05-19 베링거 인겔하임 인터내셔날 게엠베하 항콜린제와 스테로이드의 배합물 및 흡입으로 호흡기장애를 치료하기 위한 이의 용도
ATE526967T1 (de) 2003-07-31 2011-10-15 Boehringer Ingelheim Int Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
EP1925293A3 (en) 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
US9308199B2 (en) 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
US7345060B2 (en) * 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
RU2390330C2 (ru) 2003-12-31 2010-05-27 Сайдекс, Инк. Ингаляционная препаративная форма, содержащая простой сульфоалкиловый эфир гамма-циклодекстрина и кортикостероид
ES2309705T3 (es) 2004-02-06 2008-12-16 MEDA PHARMA GMBH & CO. KG Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias.
SI1713473T1 (sl) 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
US20050287077A1 (en) * 2004-02-10 2005-12-29 James E. Shipley Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds
SG153833A1 (en) * 2004-06-18 2009-07-29 Novartis Vaccines & Diagnostic Methods of treatment of endobronchial infections
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
US20060140873A1 (en) 2004-12-27 2006-06-29 Chang Heng W Aerosol pharmaceutical compositions
JP2008534480A (ja) 2005-03-24 2008-08-28 ソーセイ アールアンドディ リミテッド グリコピロニウム塩およびそれらの治療的使用
CA2603433A1 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
EP1879571A1 (de) 2005-04-23 2008-01-23 Boehringer Ingelheim International GmbH Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CA2609429A1 (en) 2005-05-31 2006-12-07 Boehringer Ingelheim International Gmbh Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
JP2008543806A (ja) 2005-06-17 2008-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療のためのｍｒｐｉｖインヒビター
CN101262846A (zh) 2005-07-15 2008-09-10 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
WO2007009164A1 (en) 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
CN100560598C (zh) * 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
AT502396B1 (de) 2005-09-01 2007-03-15 Montanuniv Leoben Verfahren zum abtrennen von verunreinigungen aus einsatzstoffen
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
PL2098248T3 (pl) 2005-12-21 2012-11-30 Meda Pharma Gmbh & Co Kg Kombinacja antycholinergików, glukokortykoidów i beta2-agonistów do leczenia chorób zapalnych
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
WO2007095041A2 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
WO2007134964A1 (en) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0614621D0 (en) * 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2008102128A2 (en) * 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP1964564A1 (en) * 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
EP2036572A1 (en) 2007-09-04 2009-03-18 Novo Nordisk A/S Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle
CN101317821B (zh) * 2007-11-15 2012-01-04 陈晓东 适用于肺部给药的超细干粉颗粒及其制备方法
KR20100099281A (ko) * 2007-12-13 2010-09-10 노파르티스 아게 유기 화합물
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
FR2940162B1 (fr) 2008-12-22 2011-02-25 Boehm & Cie Ets Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
EP2435025B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SG184352A1 (en) 2010-04-01 2012-10-30 Chiesi Farma Spa Process for preparing carrier particles for dry powders for inhalation
JP2014504260A (ja) 2010-10-15 2014-02-20 グラクソ グループ リミテッド 集合ナノ粒子状薬物製剤、その製造及び使用
RU2013142268A (ru) 2011-02-17 2015-03-27 Сипла Лимитед Фармацевтическая композиция
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
PH12013502270A1 (en) 2011-05-17 2014-01-27 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of two or more active agents
JP2016519160A (ja) 2013-05-22 2016-06-30 パール セラピューティクス，インコーポレイテッド ３つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム

Also Published As

Publication number Publication date
HUE047803T2 (hu) 2020-05-28
JP6189356B2 (ja) 2017-08-30
RU2016117972A3 (enExample) 2019-09-27
HUS1900031I1 (hu) 2019-07-29
HK1169026A1 (zh) 2013-01-18
LTC2435024I2 (enExample) 2022-06-27
MX377778B (es) 2025-03-11
RU2011154148A (ru) 2013-07-10
TWI633898B (zh) 2018-09-01
HUE029532T2 (en) 2017-03-28
LT3111926T (lt) 2020-03-25
PL2435025T3 (pl) 2017-08-31
EP3111927A1 (en) 2017-01-04
CA2763936A1 (en) 2010-12-02
HRP20161098T1 (hr) 2016-10-21
US10716753B2 (en) 2020-07-21
IL216466B (en) 2018-08-30
HUE031229T2 (en) 2017-06-28
JP2019108369A (ja) 2019-07-04
CN105193773B (zh) 2018-12-11
MX337126B (es) 2016-02-12
BRPI1011508A2 (pt) 2016-03-22
JP2015187108A (ja) 2015-10-29
TWI717511B (zh) 2021-02-01
CA2763936C (en) 2017-10-03
US20110023876A1 (en) 2011-02-03
US20150017247A1 (en) 2015-01-15
KR20120015334A (ko) 2012-02-21
RU2011154083A (ru) 2013-07-10
AR076621A1 (es) 2011-06-22
RU2011152960A (ru) 2013-07-10
CN105193773A (zh) 2015-12-30
CY1118034T1 (el) 2017-05-17
BRPI1011229B1 (pt) 2020-10-13
JP2018048150A (ja) 2018-03-29
SI3111926T1 (sl) 2020-07-31
AU2010253776B2 (en) 2015-01-22
US20110132356A1 (en) 2011-06-09
KR20120026075A (ko) 2012-03-16
DK2435025T3 (en) 2016-10-24
CN107669664B (zh) 2020-07-10
TWI707700B (zh) 2020-10-21
KR101976107B1 (ko) 2019-05-09
SI2435023T1 (sl) 2016-10-28
PT3106149T (pt) 2020-02-19
CN102458364B (zh) 2016-11-02
AR076806A1 (es) 2011-07-06
TW201919730A (zh) 2019-06-01
HUE047834T2 (hu) 2020-05-28
CY2019031I1 (el) 2019-11-27
CY2021012I2 (el) 2021-10-15
CN102753152A (zh) 2012-10-24
HK1244669A1 (zh) 2018-08-17
US20190038548A1 (en) 2019-02-07
BRPI1011220A2 (pt) 2016-03-15
AU2010253770B2 (en) 2014-12-11
RU2751771C2 (ru) 2021-07-16
RU2713404C2 (ru) 2020-02-05
AR076807A1 (es) 2011-07-06
EP3106149B1 (en) 2019-11-20
JP5823383B2 (ja) 2015-11-25
EP2435025A2 (en) 2012-04-04
ES2592536T3 (es) 2016-11-30
JP2012528200A (ja) 2012-11-12
JP6348645B2 (ja) 2018-06-27
TWI546094B (zh) 2016-08-21
WO2010138884A2 (en) 2010-12-02
MX2011012685A (es) 2012-06-12
ZA201208100B (en) 2013-07-31
SMT202000077T1 (it) 2020-03-13
US20110135737A1 (en) 2011-06-09
US20190307676A1 (en) 2019-10-10
DK2435023T3 (en) 2016-10-24
EP2435023A2 (en) 2012-04-04
CA2763939A1 (en) 2010-12-02
CY1118040T1 (el) 2017-05-17
CN102753152B (zh) 2015-09-23
PT2435024T (pt) 2016-10-13
AU2010253950B2 (en) 2014-12-04
PL2435024T3 (pl) 2017-01-31
ME03631B (me) 2020-07-20
SI2435024T1 (sl) 2016-10-28
CY1122732T1 (el) 2021-03-12
US9463161B2 (en) 2016-10-11
LUC00208I2 (enExample) 2022-10-07
LT2435024T (lt) 2016-09-26
MX2020004077A (es) 2020-07-29
LT3111927T (lt) 2020-03-25
US8808713B2 (en) 2014-08-19
HUE031283T2 (hu) 2017-07-28
HRP20200260T1 (hr) 2020-05-29
LTC2435025I2 (lt) 2021-02-10
AU2010253776A1 (en) 2011-11-24
MX350163B (es) 2017-08-29
RU2016107464A (ru) 2018-11-22
IL216468B (en) 2018-12-31
JP2012528792A (ja) 2012-11-15
IL216468A0 (en) 2012-01-31
ES2774367T3 (es) 2020-07-20
CY2019031I2 (el) 2019-11-27
AU2010253950C1 (en) 2015-09-17
JP2015199735A (ja) 2015-11-12
ZA201208101B (en) 2013-07-31
EP3111926A1 (en) 2017-01-04
SI3111927T1 (sl) 2020-08-31
SI3106149T1 (sl) 2020-07-31
RU2580315C3 (ru) 2021-06-18
EP2435024A2 (en) 2012-04-04
HUE047823T2 (hu) 2020-05-28
JP5873012B2 (ja) 2016-03-01
TWI539979B (zh) 2016-07-01
PT3111926T (pt) 2020-02-28
IL216467A0 (en) 2012-01-31
HUS2100018I1 (hu) 2021-06-28
JP2017222706A (ja) 2017-12-21
DK3106149T3 (da) 2020-02-24
MX2011012783A (es) 2012-06-28
LTPA2019014I1 (lt) 2019-07-10
HRP20161102T1 (hr) 2016-11-04
LT3106149T (lt) 2020-03-10
PL3111927T3 (pl) 2020-06-29
EP3111926B1 (en) 2019-12-11
KR20120034631A (ko) 2012-04-12
US20110132357A1 (en) 2011-06-09
TW201109049A (en) 2011-03-16
HK1169027A1 (zh) 2013-01-18
JP6169639B2 (ja) 2017-07-26
TWI792140B (zh) 2023-02-11
US20180125776A1 (en) 2018-05-10
CY1122807T1 (el) 2021-05-05
CN107412212A (zh) 2017-12-01
SMT201600329B (it) 2016-11-10
SI2435025T1 (sl) 2016-10-28
AU2010253950A1 (en) 2011-12-08
FR19C1040I1 (enExample) 2020-07-31
SMT202000108T1 (it) 2020-03-13
LT2435025T (lt) 2016-09-26
HRP20200298T1 (hr) 2020-06-12
JP2016041713A (ja) 2016-03-31
PH12017500778A1 (en) 2018-01-22
TW201936174A (zh) 2019-09-16
PL3106149T3 (pl) 2020-06-01
US20250009652A1 (en) 2025-01-09
RU2580315C2 (ru) 2016-04-10
TWI632926B (zh) 2018-08-21
CA2763941A1 (en) 2010-12-02
KR20180130602A (ko) 2018-12-07
RU2586297C2 (ru) 2016-06-10
TW201109050A (en) 2011-03-16
HK1169307A1 (zh) 2013-01-25
ES2593429T3 (es) 2016-12-09
MX350164B (es) 2017-08-29
CY1122749T1 (el) 2021-03-12
CN102596176B (zh) 2017-09-19
WO2010138868A3 (en) 2011-04-28
DK3111927T3 (da) 2020-03-09
RU2016117972A (ru) 2018-10-29
US20210186861A1 (en) 2021-06-24
BRPI1011229B8 (pt) 2021-05-25
TW201700123A (zh) 2017-01-01
ZA201208102B (en) 2013-09-25
AU2010253770B9 (en) 2015-02-12
HRP20200166T1 (hr) 2020-05-15
NL300995I1 (enExample) 2019-06-24
EP2435023B1 (en) 2016-07-06
WO2010138862A2 (en) 2010-12-02
NO2019026I1 (no) 2019-06-13
NO2021019I1 (no) 2021-05-12
PT3111927T (pt) 2020-03-03
ES2589135T3 (es) 2016-11-10
DK3111926T3 (da) 2020-03-02
TW201808372A (zh) 2018-03-16
US20170071850A1 (en) 2017-03-16
WO2010138862A3 (en) 2011-04-14
JP2018008942A (ja) 2018-01-18
JP2012528199A (ja) 2012-11-12
WO2010138868A2 (en) 2010-12-02
BRPI1011229A2 (pt) 2016-03-15
EP2435025B1 (en) 2016-07-06
KR20170070274A (ko) 2017-06-21
PL3111926T3 (pl) 2020-06-29
EP2435024B1 (en) 2016-07-06
SMT201600326B (it) 2016-11-10
SMT201600327B (it) 2016-11-10
WO2010138884A3 (en) 2011-04-21
KR101926060B1 (ko) 2018-12-06
TWI695723B (zh) 2020-06-11
JP5873013B2 (ja) 2016-03-01
CN102458364A (zh) 2012-05-16
CN107669664A (zh) 2018-02-09
SMT202000109T1 (it) 2020-03-13
TW201109051A (en) 2011-03-16
TW201642836A (zh) 2016-12-16
ES2772253T3 (es) 2020-07-07
DK2435024T3 (en) 2016-10-24
EP3111927B1 (en) 2019-12-11
RU2015151358A3 (enExample) 2019-07-29
MX393243B (es) 2025-03-24
RU2016107464A3 (enExample) 2019-08-19
PT2435025T (pt) 2016-11-11
TWI646980B (zh) 2019-01-11
ES2774391T3 (es) 2020-07-20
CY2021012I1 (el) 2021-10-15
AU2010253770A1 (en) 2011-11-24
PL2435023T3 (pl) 2017-06-30
CY1118030T1 (el) 2017-05-17
TW202114642A (zh) 2021-04-16
IL216467B (en) 2018-12-31
KR101748892B1 (ko) 2017-06-19
LUC00124I2 (enExample) 2019-12-27
US20170112759A1 (en) 2017-04-27
RU2020102859A (ru) 2021-07-26
NL300995I2 (nl) 2019-10-29
PT2435023T (pt) 2016-10-14
RU2015151358A (ru) 2019-01-16
HK1247095A1 (zh) 2018-09-21
HK1218867A1 (zh) 2017-03-17
LT2435023T (lt) 2016-09-26
HRP20161101T1 (hr) 2016-11-04
EP3106149A1 (en) 2016-12-21
KR20190049943A (ko) 2019-05-09
LUC00124I1 (enExample) 2019-06-13
JP6876734B2 (ja) 2021-05-26
FR19C1040I2 (fr) 2020-07-31
CN107412212B (zh) 2021-01-22
MX2011012684A (es) 2012-05-23
ZA201108275B (en) 2023-04-26
CN102596176A (zh) 2012-07-18
BRPI1011220B1 (pt) 2020-03-10
JP6492124B2 (ja) 2019-03-27
IL216466A0 (en) 2012-01-31
KR20170104003A (ko) 2017-09-13

Similar Documents

Publication Publication Date Title
NL300995I1 (enExample)
BE2015C040I2 (enExample)
BRPI0925311A2 (enExample)
BR112012003062A2 (enExample)
BRPI0924307A2 (enExample)
BRPI1006562A2 (enExample)
BR112012012396A2 (enExample)
BRPI1006661A2 (enExample)
BR112012000607A2 (enExample)
BR122021004633A2 (enExample)
BR122017024704A2 (enExample)
BR112012012080A2 (enExample)
BRPI1006206A2 (enExample)
BRPI0924534A2 (enExample)
BRPI1005795A2 (enExample)
BR122019005883A2 (enExample)
BR112012001263A2 (enExample)
BR112012000159A2 (enExample)
BR112012014856A2 (enExample)
BRPI1005817A2 (enExample)
BR112012002627A2 (enExample)
BR112012000255A2 (enExample)
BRPI0925022A2 (enExample)
BR122017013721A2 (enExample)
BR112012016234A2 (enExample)